Electra Therapeutics (NASDAQ:ETRA) Director Carl Gordon Buys 156,091 Shares of Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Carl Gordon acquired 156,091 shares of Electra Therapeutics stock in a transaction dated Thursday, November 5th. The stock was purchased at an average price of $7.31 per share, with a total value of $1,141,025.21. Following the completion of the purchase, the director directly owned 5,220,762 shares of the company’s stock, valued at $38,163,770.22. The trade was a 3.08% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Electra Therapeutics Stock Down 7.8%

Shares of NASDAQ ETRA traded down $0.62 during trading hours on Thursday, hitting $7.35. 524,786 shares of the stock were exchanged, compared to its average volume of 481,923. Electra Therapeutics, Inc. has a one year low of $6.86 and a one year high of $15.50.

Analyst Ratings Changes

ETRA has been the topic of several research analyst reports. TD Cowen began coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. initiated coverage on Electra Therapeutics in a research report on Thursday, October 22nd. They set an “overweight” rating and a $36.00 price objective for the company. Wall Street Zen upgraded Electra Therapeutics to a “hold” rating in a research note on Saturday, September 26th. HC Wainwright began coverage on Electra Therapeutics in a research note on Monday, October 26th. They set a “buy” rating and a $30.00 target price for the company. Finally, Evercore assumed coverage on Electra Therapeutics in a report on Tuesday, October 13th. They issued an “outperform” rating and a $36.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $33.50.

About Electra Therapeutics

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function.

Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.